Regeneron's Eylea Soars, But Praluent Is Slow Out Of The Gate
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals Inc. turned in a strong quarter for its ophthalmology blockbuster Eylea (aflibercept), and predicts 20% growth for the drug's fifth year on the market. But the attention-grabber out of its fourth quarter and full-year 2015 earnings report was the sluggish launch of PCSK9 inhibitor Praluent (alirocumab).
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian
Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.